Valuation: Evotec SE

Market Cap 61Cr 70Cr 57Cr 52Cr 98Cr 6.73TCr 100Cr 677.99Cr 264.89Cr 3.31TCr 262.41Cr 256.76Cr 11TCr P/E 2026 *
-4.01x
P/E 2027 * -10x
Enterprise Value 66Cr 75Cr 61Cr 56Cr 105.1Cr 7.19TCr 106.72Cr 723.82Cr 282.79Cr 3.53TCr 280.15Cr 274.11Cr 12TCr EV / Sales 2026 *
1.09x
EV / Sales 2027 * 0.98x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 43 22/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
+1.30%-.--% - - 70Cr
+1.07%-3.49%-3.35%+10.44% 4.69TCr
+0.25%+1.65%+399.22%+634.87% 4.02TCr
-0.27%+4.45%+11.81%+65.64% 3.62TCr
+0.35%+0.87%+4.46%-10.16% 3.47TCr
+3.14%+1.02%+4.76%+40.92% 2.79TCr
-0.73%+11.84%+34.39%+134.36% 1.68TCr
+0.47%-2.74% - - 1.67TCr
+0.42%-5.52%-3.43%+9.03% 1.31TCr
-2.68%-2.49%-11.36%-33.61% 1.27TCr
Average +0.33%+0.83%+54.56%+106.44% 2.73TCr
Weighted average by Cap. +0.48%+0.91%+74.42%+136.27%

Financials

2026 *2027 *
Net sales 60Cr 68Cr 56Cr 51Cr 96Cr 6.57TCr 98Cr 662.22Cr 258.72Cr 3.23TCr 256.31Cr 250.78Cr 11TCr 74Cr 84Cr 68Cr 63Cr 118.03Cr 8.07TCr 119.85Cr 812.92Cr 317.6Cr 3.97TCr 314.63Cr 307.85Cr 14TCr
Net income -15Cr -17Cr -14Cr -13Cr -24Cr -1.61TCr -24Cr -162.52Cr -63Cr -793.31Cr -63Cr -62Cr -2.74TCr -4.75Cr -5.4Cr -4.41Cr -4.05Cr -7.61Cr -520.32Cr -7.73Cr -52Cr -20Cr -255.81Cr -20Cr -20Cr -884.46Cr
Net Debt 4.15Cr 4.73Cr 3.86Cr 3.54Cr 6.65Cr 455.03Cr 6.76Cr 46Cr 18Cr 223.71Cr 18Cr 17Cr 773.47Cr 11Cr 12Cr 9.78Cr 8.97Cr 17Cr 1.15TCr 17Cr 116.14Cr 45Cr 566.9Cr 45Cr 44Cr 1.96TCr
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-